Sun Pharmaceutical Industries Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty 100 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sun Pharma's Board approved audited standalone and consolidated financial results for Q4 and FY25 with a clean (unmodified) auditor's opinion from SRBC & Co LLP. On a standalone basis, FY25 revenue from operations rose about 13.5% year-on-year to roughly Rs. 23,003 crore, while profit after tax surged nearly 50% to Rs. 4,283 crore; basic EPS climbed to Rs. 17.8 from Rs. 11.9. The company reported no exceptional items in FY25, compared with Rs. 219 crore of exceptional charges in FY24 (intangible impairment plus a Lipitor-related legal settlement). For Q4 FY25 standalone, revenue grew about 27% YoY to Rs. 7,186 crore and profit after tax jumped to Rs. 2,000 crore from Rs. 868 crore. The Board recommended a final dividend of Rs. 5.50 per share, taking the total FY25 payout to Rs. 16 per share (Rs. 10.50 interim + Rs. 5.50 final), with a record date of July 7, 2025 and AGM scheduled for July 31, 2025.
Strong double-digit earnings growth, a clean audit report, and the absence of exceptional items this year should support a positive investor reaction, while the higher total dividend rewards shareholders. Governance changes — appointment of Ms. Vidhi Shanghvi as Whole-time Director and the retirement of long-time director Mr. Sudhir Valia — are also worth tracking.